CYTR, CytRx Corporation CYTR reported that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors, primarily soft tissue sarcomas, are being presented today at the American Society of Clinical Oncology (ASCO) conference in Chicago. All patients in the study had either not responded to or relapsed after treatment with between one and three prior chemotherapy regimens. Clinical benefit (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) with INNO-206 at the maximum tolerated dose was shown in 10 of 13 (76.9%) evaluable patients with relapsed or refractory soft tissue sarcoma. Each year in the U.S. nearly 11,000 new cases of soft tissue sarcoma are diagnosed and almost 4,000 deaths are reported due to this cancer. Patients with advanced soft tissue sarcoma who can no longer be treated with surgery and have relapsed or were refractory to prior chemotherapies have a poor prognosis, with fewer than 15% living past five years. CYTR has been granted orphan drug designation by the FDA for the treatment of patients with soft tissue sarcomas. CYTR plans to meet with the FDA to discuss a Phase 3 pivotal trial design with INNO-206 as a third-line therapy in soft tissue sarcoma patients. CYTR is a biopharmaceutical research and development company specializing in oncology. More about CYTR at www.cytrx.com. ORLY, O'Reilly Automotive, Inc. ORLY reported that its Board of Directors approved a resolution to increase the authorization amount under its share repurchase program by an additional 500 million, raising the aggregate authorization under the program to 2 billion. The additional 500 million authorization is effective for a three-year period, beginning on June 1, 2012. Stock repurchases under the program may be made from time to time, as ORLY deems appropriate, solely through open market purchases effected through a broker dealer at prevailing market prices, based on a variety of factors such as price, corporate requirements and overall market conditions. There can be no assurance as to the number of shares ORLY will purchase, if any. The share repurchase program may be increased or otherwise modified, renewed, suspended or terminated by the Company at any time, without prior notice. ORLY is one of
the largest specialty retailers of automotive aftermarket parts, tools, supplies, equipment and accessories in the United States, serving both the do-it-yourself and professional service provider markets. More about ORLY at www.oreillyauto.com TEVA, Teva Pharmaceutical Industries Ltd. TEVA reported that Dr. Phillip Frost, Chairman of the Board of Directors, purchased one million TEVA American Depositary Shares on Wednesday, May 30, 2012, the first day of trading on the New York Stock Exchange, at prices ranging from 37.82 to 39.57. TEVA is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. More about TEVA at www.tevapharm.com THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.